ArticleFrontiers in oncology2021

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway.

Amin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.